Latest Breaking News On - Hich can be easily updated with emerging variants leading to large scale production - Page 1 : comparemela.com

NEW DELHI - India on Thursday launched the "world's first" intranasal Covid-19 vaccine developed by local pharmaceutical firm Bharat Biotech. Health Minister Mansukh Mandaviya launched the iNcovacc vaccine on a day when the country is celebrating its 74th Republic Day. "iNcovacc is the world's first intranasal Covid-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose," a Health Ministry's statement said on Thursday. Calling it a "mighty display of India's research and innovation prowess under Prime Minister Narendra Modi's leadership," Mandaviya said it is a "historic achievement and a testimony to the innovative zeal of our scientists." The ministry said the vaccine is cost-effective and does not require "syringes, needles, alcohol wipes, bandage, etc., saving costs related to procurement, distribution, storage, and biomedical waste disposal, that is routinely required for i

Narendra modiMansukh mandaviyaHealth ministryMinister mansukh mandaviyaPrime minister narendra modiNew delhi india on thursday launched the quot world 39s first intranasal covid 19 vaccine developed by local pharmaceutical firm bharat biotech health minister mansukh mandaviya incovacc ona day when country is celebrating its 74th republic to receive approval for primary 2 dose scheduleNd asa heterologous booster doseUota health ministry 39s statement said on thursday calling ita quot mighty display of india research and innovation prowess under prime minister narendra modi leadershipUot mandaviya said it isa quot historic achievement anda testimony to the innovative zeal of our scientists ministry vaccine is cost effective and does not require syringesAlcohol wipesAving costs related to procurementNd biomedical waste disposalHat is routinely required for injectable vaccines quot it utilizesa vector based platformHich can be easily updated with emerging variants leading to large scale productionIthina few months these rapid response timelines combined with the ability of cost effective and easy intranasal delivery makes it an ideal vaccine to address future infectious diseasesUot the statement saida by manufacturer said rollout of vaccine is expected to begin in private hospitals that have placed advance orders quot initial manufacturing capacity several million doses per annum has been established